$RSII WILL B THE NEXT OWCP AND MORE! PLEASE DD IT NOW, AND

New Post Public Reply Private Reply Replies (0) Message Board
southswell
2,008
$RSII WILL B THE NEXT OWCP AND MORE! PLEASE DD IT NOW, AND HELP LOCK THE FLOAT BY SLAPPING THE ASK! MM'S ARXS AND ASCM ARE SHORT, HIDING BEHIND NITE AND JUMPING MM'S FOR SHARES! CRAZY! REMEMBER, THESE ARE THE TOP TWO MM'S THAT GOT CAUGHT SHORT OWCP, C HOW THAT WORKED OUT FOR THEM.


$OWCP VS. $RSII Med cannabis sector producst but different biz models>>>

Med Cannabis is very safe and not under the same regs as rec cannabis.

RSII REVIEW OF CONF. CALL on 2/24/17 & DD:

If you missed the Conf. Call yesterday ...here is a good summary and some DD:

RSII business model confirmed today on CC... There model is sort of like OWCP's but without all the FDA guidelines, indications, submission, trials, and all the COSTS that going into getting a product ready to submit to the FDA...That is very risky, costly and may never earn a dime in profit or revenue.....NOW RSII will have A team of pharmacists, chemists, physicians, etc..will be creating pharm grade medicinal cannabis product with the highest quality of ingredients and calibrated with precise accuracy. All forms of cannabis, but mainly topicals, creams, and orals. ..No one in the industry is doing this with precise accuracy...they will be the first... They come short of announcing they will supply to NWAV clinics (Alternative Medicine Centers of America) but if you read between the lines, its pretty much a done deal....Robert Weber is the CEO of both and he basicly said they had to separate the disposing/compounding side from the patient/clinic side as per their lawyers due to regulations. Medicinal Cannabis will be branded and marketed under their name Rising Biosciences. Mail order, clinics, prescribing md's, etc....Huge market.

They buy the purest ingredients and compound them to the form, exact dosage, % of THC, and dispense.. There is NO FDA here...no patents etc...Millions of dollars and years for studies are NOT needed like OWCP...and they might not even get FDA approval for psoriasis ...10% get approved of submissions to the fda. Also...they have a built in customer base already in NWAV clinics... .Alternative Medicine Centers of America. Robert Weber is the CEO of NWAV and RSII.

In other word...OWCP like (featuring topicals, creams, orals mainly but all forms of medicinal cannabis) but no FDA route..compounding pharmacy with labs and physicians, chemists, pharmacists....etc...Dont have to wait years for FDA approval.. .Products will be available quickly and revenues will follow fast..... THERE IS NO BETTER MODEL IN THE MEDICINAL CANNABIS INDUSTRY....SPENDING MILLIONS ON TRIALS, STUDYS, PROTOCOL REQUIREMENTS, AND THE 1-2 YR TIME FRAME FROM PHASE 1-2 STUDIES....PLUS THERE ARE NO GUARANTEES.....AND 10% OF PRODUCT SUBMISSIONS EVER GET APPROVED BY THE FDA...10% THATS IT. LIKE I SAID, FOR THE MEDICINAL CANNABIS SPACE....NOTHING BETTER THAN THE RSII MODEL.

So lets compare OWCP to RSII....

REGARDING RSII's CURRENT MARKET CAP: The market cap valuation of RSII is based on current share price...RSII is $3m at .0135...my point is RSII is EXTREMELY UNDERVALUED at these prices...hope this helps. Lets put $75M MC valuation on RSII which is imo about right in these stage and the sector. That would put the PPS of RSII approximately at about .20 cents...and that can only go up from here once they start rolling out the business and scaling it.

1- market valuation OWCFP $325M $2.19 pps vs RSII $5M .0135 pps
2- OWCP- make take years and cost millions of dollars to do studies to submit a product to the FDA for approval...and only 10% ever get approved....VS. S RSII- will have precise forms of med cannabis ingredients to be compound and dispensed in different forms as soon as they start which is very soon. No studies required...Cash requirements minimal, Revs immediate.
3- OWCP Float about 150M vs. RSII about 225M

"Our team has met with business operators that have real experience and expertise in multiple states and several business verticals within the cannabis industry," commented Management. "The business focus will center on working with physicians and pharmacists groups on the Research and Development of new, cutting edge treatments within the medical cannabis industry. Shareholders are encouraged to stay tuned to upcoming press releases and social media updates, where a detailed plan for RSII's entrance into this sector will be outlined."

Look & Listen at the video on Facebook with outside one of the labs of a compounding pharmacy: https://www.facebook.com/RisingIndiaUSA/?hc_r...mp;fref=nf

1- What is “compounding”?
In general, compounding is a practice in which a licensed pharmacist, a licensed physician, or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.

2-Why do some patients need compounded drugs?
Sometimes, the health needs of a patient cannot be met by an FDA-approved medication. For example: if a patient has an allergy and needs a medication to be made without a certain dye; or
if an elderly patient or a child can’t swallow a pill and needs a medicine in a liquid form that is not otherwise available.

3-Are compounded drugs approved by the FDA?
Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, or effectiveness of compounded drugs. Consumers and health professionals rely on the drug approval process to ensure that drugs are safe and effective and made in accordance with Federal quality standards. Compounded drugs also lack an FDA finding of manufacturing quality before such drugs are marketed.
Generally, state boards of pharmacy will continue to have primary responsibility for the day-to-day oversight of state-licensed pharmacies that compound drugs in accordance with the conditions of section 503A of the FDCA, although FDA retains some authority over their operations. However, outsourcing facilities that register under section 503B are regulated by FDA and must comply with CGMP requirements and will be inspected by FDA according to a risk-based schedule.


Here is an very interesting post for RSII...Seems that OWCP Company strategies and mindset of investors is changing....Our RSII MODEL is now being talked about on the OWCP board....RSII has compounding labs/pharmacies already in place and we seen one of them with a team of pharmacists, chemists, physicians, etc. that they will be branding and scaling under Rising BioSciences...The CC confirmed it...
I believe the pharmacist/chemist with 30YRS of experience in compounding and has done alot with medicinal cannabis forms said."We will revolutionize the med cannabis industry...no one else is doing what we will be doing in this space." That is pretty much word for word what he said.

GLTA
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 120

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
Birla Carbon's Rayong Bet Tightens Asian Supply Lines

Updated Category News Views 105

Rayong just became a much louder pin on Asia's industrial map. Birla Carbon has inaugurated a 120 kMT carbon black plant in Thailand, and the significance is bigger than a ribbon-cutting photo. This is a capacity-and-location move aimed squarely at the uncomfortable part of industrial supply chains: customers need material when they need it, not after it has spent weeks...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 173

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 119

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 131

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 80

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading
EmTech AI 2027 Puts AI Ambitions Through Reality Test

Updated Category News Views 111

A three-day gathering cannot settle AI's biggest arguments, but MIT Technology Review has picked the right fight for EmTech AI 2027: make the industry face a Reality Test. The conference runs May 11–13, 2027, at MIT's campus and online, and that theme lands because the AI conversation has spent plenty of time admiring the engine while skipping the ugly maintenance bill....

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 157

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Curis Advances CLL Treatment With Promising Start

Updated Category News Views 76

You know, every now and then, a glimmer of potential bites back against the usual cancer battle headlines. Today, Curis, Inc. (NASDAQ: CRIS) is that flickering hope in the often murky world of biotech, making moves to stir things up with its TakeAim CLL study. Let's do a deep dive into exactly what this could mean for the world battling chronic lymphocytic leukemia....

Continue Reading
Robust Growth Expected in Antimicrobial Coatings Market

Updated Category News Views 243

Antimicrobial Coating Market Predicted to Surge The Global antimicrobial coating market is on track for remarkable growth, projected to reach US$ 8.82 billion by 2031 from US$ 3.78 billion in 2023. This substantial growth corresponds to a compound annual growth rate (CAGR) of 11.2% throughout the forecast period. Growing Demand for Antimicrobial Coatings One of the...

Continue Reading
Royal Unibrew A/S Transactions Report by Management Personnel

Updated Category News Views 121

Recent Transactions by Management at Royal Unibrew A/S Royal Unibrew A/S, a prominent player in the beverage industry, has recently made important disclosures regarding share transactions executed by its key management personnel. This announcement is made in accordance with the regulations aimed at promoting transparency in the market. Transaction Details Overview This...

Continue Reading
Innovative Support Post Enhances Horse Racing Safety Measures

Updated Category News Views 124

Innovative Design for Racing Safety Recently, a creative inventor conceptualized an advanced support post specifically for horse racing track railings. This inventive solution was born from a desire to lessen the risk of injury to jockeys and horses. The inventor aimed to create a product that enhances safety on race tracks while providing peace of mind for everyone...

Continue Reading
Aurigo Software Partners with Philadelphia for Infrastructure Growth

Updated Category News Views 258

Aurigo Software Partners with Philadelphia for Infrastructure Growth Aurigo Software, known for its expertise in capital planning and construction management, has announced a significant partnership with the City of Philadelphia. This multiyear contract aims to leverage Aurigo's leading product suite, Masterworks, to improve infrastructure program management for the city....

Continue Reading